GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD and Releasing Inducible IL-18.

Chimeric antigen receptor (CAR)-engineered T cells can be highly effective in the treatment of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus, approaches using 4 advanced CAR T cells secreting immunomodulatory cytokines upon CAR signaling, known as TRUCKs (""), are currently under investigation. Based on our previous development and validation of automated and closed processing for GMP-compliant manufacturing of CAR T cells, we here present the proof of feasibility for translation of this method to TRUCKs.